Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hypertension

Free Subscription Articles published in Eur J Pharmacol Retrieve available abstracts of 50 articles: HTML format

Single Articles

October 2023
1. CHAI L, Wang Q, Wang Y, Li D, et al
   Downregulation of PDCD4 through STAT3/ATF6/autophagy mediates MIF-induced PASMCs proliferation/migration and vascular remodeling.
   Eur J Pharmacol. 2023;956:175968.
   PubMed     Abstract available
   
   
   
2. GUTIERREZ A, Gomez Del Val A, Contreras C, Olmos L, et al
   Calcium handling coupled to the endothelin ET(A) and ET(B) receptor-mediated vasoconstriction in resistance arteries: Differential regulation by PI3K, PKC and RhoK.
   Eur J Pharmacol. 2023;956:175948.
   PubMed     Abstract available
   
   
   September 2023
3. NOAH AA, El-Mezayen NS, El-Ganainy SO, Darwish IE, et al
   Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl(4)-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-beta and gal-1/NRP-1/VEGFR2 pathways.
   Eur J Pharmacol. 2023 Sep 26:176066. doi: 10.1016/j.ejphar.2023.176066.
   PubMed     Abstract available
   
   
   
4. VALOVIC P, Behuliak M, Vaneckova I, Zicha J, et al
   Impaired vascular beta-adrenergic relaxation in spontaneously hypertensive rats: The differences between conduit and resistance arteries.
   Eur J Pharmacol. 2023 Sep 12:176045. doi: 10.1016/j.ejphar.2023.176045.
   PubMed     Abstract available
   
   
   August 2023
5. V B, Wright G, Sundhar M, Ravikumar TS, et al
   Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF.
   Eur J Pharmacol. 2023 Aug 25:176010. doi: 10.1016/j.ejphar.2023.176010.
   PubMed     Abstract available
   
   
   June 2023
6. CHEN M, Hu Q, Wang S, Tao L, et al
   1,8-Cineole ameliorates endothelial injury and hypertension induced by L-NAME through regulation of autophagy via PI3K/mTOR signaling pathway.
   Eur J Pharmacol. 2023 Jun 26:175863. doi: 10.1016/j.ejphar.2023.175863.
   PubMed     Abstract available
   
   
   
7. DOURADO TMH, Assis VO, Awata WMC, de Mello MMB, et al
   Mineralocorticoid receptors contribute to ethanol-induced vascular hypercontractility through reactive oxygen species generation and up-regulation of cyclooxygenase 2.
   Eur J Pharmacol. 2023;949:175723.
   PubMed     Abstract available
   
   
   May 2023
8. LI Q, Fang Y, Peng DW, Li LA, et al
   Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
   Eur J Pharmacol. 2023 May 12:175754. doi: 10.1016/j.ejphar.2023.175754.
   PubMed     Abstract available
   
   
   
9. ABDULKAREEM AO, Tiwari P, Lone ZR, Iqbal H, et al
   Corrigendum to "Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension" [Eur. J. Pharmacol. 943 (2023) 175558].
   Eur J Pharmacol. 2023 May 3:175750. doi: 10.1016/j.ejphar.2023.175750.
   PubMed    
   
   
   March 2023
10. MARTINEZ VR, Martins Lima A, Stergiopulos N, Velez Rueda JO, et al
    Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy.
    Eur J Pharmacol. 2023 Mar 14:175654. doi: 10.1016/j.ejphar.2023.175654.
    PubMed     Abstract available
    
    
    
11. ABDELAZEEM H, Tu L, Thuillet R, Ottaviani M, et al
    AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery.
    Eur J Pharmacol. 2023 Mar 11:175579. doi: 10.1016/j.ejphar.2023.175579.
    PubMed     Abstract available
    
    
    February 2023
12. ZHAN Q, Zhao J, Liu L, Wang B, et al
    Integrated network pharmacology and molecular docking analyses of the mechanisms underlying the antihypertensive effects of lotusine.
    Eur J Pharmacol. 2023 Feb 28:175622. doi: 10.1016/j.ejphar.2023.175622.
    PubMed     Abstract available
    
    
    
13. JIANG Y, Huang J, Xia Y, Sun Z, et al
    Hypoxia activates GPR146 which participates in pulmonary vascular remodeling by promoting pyroptosis of pulmonary artery endothelial cells.
    Eur J Pharmacol. 2023;941:175502.
    PubMed     Abstract available
    
    
    
14. HERTEL M, Preissner S, Gohlke BO, Kuebler WM, et al
    Real-world evidence for beneficial effects of dipyrone in 4,278 patients with pulmonary hypertension - Analysis of the risk of ventilation, hospitalization, and agranulocytosis.
    Eur J Pharmacol. 2023 Feb 6:175567. doi: 10.1016/j.ejphar.2023.175567.
    PubMed     Abstract available
    
    
    January 2023
15. ABDULKAREEM AO, Tiwari P, Lone ZR, Iqbal H, et al
    Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension.
    Eur J Pharmacol. 2023 Jan 30:175558. doi: 10.1016/j.ejphar.2023.175558.
    PubMed     Abstract available
    
    
    
16. NIE X, Wu Z, Shang J, Zhu L, et al
    Curcumol suppresses endothelial-to-mesenchymal transition via inhibiting the AKT/GSK3beta signaling pathway and alleviates pulmonary arterial hypertension in rats.
    Eur J Pharmacol. 2023 Jan 24:175546. doi: 10.1016/j.ejphar.2023.175546.
    PubMed     Abstract available
    
    
    December 2022
17. ZENG Z, Zhou X, Zhu Y, Huang X, et al
    Kruppel-like Factor 7 inhibits proliferation and migration of pulmonary smooth muscle cells via p21 activation.
    Eur J Pharmacol. 2022;940:175473.
    PubMed     Abstract available
    
    
    September 2022
18. CHEN S, Sun P, Li Y, Shen W, et al
    Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension.
    Eur J Pharmacol. 2022 Sep 10:175262. doi: 10.1016/j.ejphar.2022.175262.
    PubMed     Abstract available
    
    
    
19. YAN J, Honglei Y, Yun W, Sheng D, et al
    Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway.
    Eur J Pharmacol. 2022 Sep 7:175254. doi: 10.1016/j.ejphar.2022.175254.
    PubMed     Abstract available
    
    
    August 2022
20. GHAFOURI-FARD S, Shirvani-Farsani Z, Hussen BM, Taheri M, et al
    The key roles of non-coding RNAs in the pathophysiology of hypertension.
    Eur J Pharmacol. 2022 Aug 19:175220. doi: 10.1016/j.ejphar.2022.175220.
    PubMed     Abstract available
    
    
    
21. TURHAN K, Alan E, Yetik-Anacak G, Sevin G, et al
    H2S releasing sodium sulfide protects against pulmonary hypertension by improving vascular responses in monocrotaline-induced pulmonary hypertension.
    Eur J Pharmacol. 2022 Aug 5:175182. doi: 10.1016/j.ejphar.2022.175182.
    PubMed     Abstract available
    
    
    July 2022
22. KODAMA T, Otani K, Okada M, Yamawaki H, et al
    Eukaryotic elongation factor 2 kinase inhibitor, A484954 inhibits perivascular sympathetic nerve stimulation-induced vasoconstriction in isolated renal artery.
    Eur J Pharmacol. 2022;926:175042.
    PubMed     Abstract available
    
    
    
23. WANG C, Han L, Wang T, Wang Y, et al
    Cyclosporin A up-regulated thromboxane A2 receptor through activation of MAPK and NF-kappaB pathways in rat mesenteric artery.
    Eur J Pharmacol. 2022;926:175034.
    PubMed     Abstract available
    
    
    
24. IQBAL H, Yadav P, Verma AK, Mishra D, et al
    Anti-inflammatory, anti-oxidant and cardio-protective properties of novel fluorophenyl benzimidazole in L-NAME-induced hypertensive rats.
    Eur J Pharmacol. 2022 Jul 2:175132. doi: 10.1016/j.ejphar.2022.175132.
    PubMed     Abstract available
    
    
    June 2022
25. ZHAO X, Li L, Li S, Liu J, et al
    Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3.
    Eur J Pharmacol. 2022 Jun 20:175115. doi: 10.1016/j.ejphar.2022.175115.
    PubMed     Abstract available
    
    
    
26. LI XT, Zhang YP, Zhang MW, Zhang ZZ, et al
    Sirtuin 7 serves as a promising therapeutic target for cardiorenal diseases.
    Eur J Pharmacol. 2022;925:174977.
    PubMed     Abstract available
    
    
    May 2022
27. LI L, Su XL, Bai TT, Qin W, et al
    New paeonol derivative C302 reduces hypertension in spontaneously hypertensive rats through endothelium-dependent and endothelium-independent vasodilation.
    Eur J Pharmacol. 2022 May 27:175057. doi: 10.1016/j.ejphar.2022.175057.
    PubMed     Abstract available
    
    
    
28. BANKS TE, Rajapaksha M, Zhang LH, Bai F, et al
    Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
    Eur J Pharmacol. 2022 May 26:175048. doi: 10.1016/j.ejphar.2022.175048.
    PubMed     Abstract available
    
    
    
29. JOO TURONI CM, Maranon RO, Alberstein RA, Sanchez RS, et al
    A novel endothelium-independent effect of insulin on basal vascular tone in cafeteria diet-induced hypertensive rats.
    Eur J Pharmacol. 2022;925:174997.
    PubMed     Abstract available
    
    
    March 2022
30. SHIMIZU S, Nagao Y, Kurabayashi A, Shimizu T, et al
    Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats.
    Eur J Pharmacol. 2022 Mar 22:174911. doi: 10.1016/j.ejphar.2022.174911.
    PubMed     Abstract available
    
    
    January 2022
31. CHEN D, Yuan T, Chen Y, Zhang H, et al
    DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
    Eur J Pharmacol. 2022 Jan 26:174779. doi: 10.1016/j.ejphar.2022.174779.
    PubMed     Abstract available
    
    
    December 2021
32. DIAS CJ, Costa HA, Alves Dias-Filho CA, Ferreira AC, et al
    Carvacrol reduces blood pressure, arterial responsiveness and increases expression of MAS receptors in spontaneously hypertensive rats.
    Eur J Pharmacol. 2021 Dec 22:174717. doi: 10.1016/j.ejphar.2021.174717.
    PubMed     Abstract available
    
    
    
33. ZHENG L, Zhao Z, Lin J, Li H, et al
    Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.
    Eur J Pharmacol. 2021 Dec 20:174713. doi: 10.1016/j.ejphar.2021.174713.
    PubMed     Abstract available
    
    
    
34. TOBA H, Ikemoto MJ, Kobara M, Nakata T, et al
    Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive r
    Eur J Pharmacol. 2021 Dec 3:174681. doi: 10.1016/j.ejphar.2021.174681.
    PubMed     Abstract available
    
    
    November 2021
35. KODAMA T, Kameshima S, Otani K, Okada M, et al
    Eukaryotic elongation factor 2 kinase inhibitor, A484954 induces diuretic effect via renal vasorelaxation in spontaneously hypertensive rats.
    Eur J Pharmacol. 2021 Nov 18:174637. doi: 10.1016/j.ejphar.2021.174637.
    PubMed     Abstract available
    
    
    October 2021
36. BALERA BRITO VG, Patrocinio MS, Alves Barreto AE, Tfaile Frasnelli SC, et al
    Telmisartan impairs the in vitro osteogenic differentiation of mesenchymal stromal cells from spontaneously hypertensive male rats.
    Eur J Pharmacol. 2021;912:174609.
    PubMed     Abstract available
    
    
    September 2021
37. ALVES BARRETO AE, Balera Brito VG, Patrocinio MS, Ballassoni BB, et al
    beta1-adrenergic receptor but not beta2 mediates osteogenic differentiation of bone marrow mesenchymal stem cells in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Sep 20:174515. doi: 10.1016/j.ejphar.2021.174515.
    PubMed     Abstract available
    
    
    
38. CORBOZ MR, Plaunt AJ, Malinin V, Li Z, et al
    Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Eur J Pharmacol. 2021 Sep 8:174484. doi: 10.1016/j.ejphar.2021.174484.
    PubMed     Abstract available
    
    
    
39. BADZYNSKA B, Vaneckova I, Sadowski J, Hojna S, et al
    Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Sep 4:174445. doi: 10.1016/j.ejphar.2021.174445.
    PubMed     Abstract available
    
    
    August 2021
40. HU J, Yang Z, Chen X, Kuang S, et al
    Thromboxane A2 is involved in the development of hypertension in chronic kidney disease rats.
    Eur J Pharmacol. 2021 Aug 17:174435. doi: 10.1016/j.ejphar.2021.174435.
    PubMed     Abstract available
    
    
    
41. ARAUJO ENCINAS JF, Foncesca Peiro CH, Perez MM, Santos Raimundo JR, et al
    Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review.
    Eur J Pharmacol. 2021;905:174180.
    PubMed     Abstract available
    
    
    July 2021
42. HUANG N, Zhu TT, Liu T, Ge XY, et al
    Aspirin ameliorates pulmonary vascular remodeling in pulmonary hypertension by dampening endothelial-to-mesenchymal transition.
    Eur J Pharmacol. 2021;908:174307.
    PubMed     Abstract available
    
    
    
43. BATISTA RIM, Nogueira RC, Ferreira GC, Oliveira-Paula GH, et al
    Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine.
    Eur J Pharmacol. 2021;907:174314.
    PubMed     Abstract available
    
    
    
44. LV Y, Ma P, Wang J, Xu Q, et al
    Betaine alleviates right ventricular failure via regulation of Rho A/ROCK signaling pathway in rats with pulmonary arterial hypertension.
    Eur J Pharmacol. 2021 Jul 7:174311. doi: 10.1016/j.ejphar.2021.174311.
    PubMed     Abstract available
    
    
    June 2021
45. ZHU JX, Ling W, Xue C, Zhou Z, et al
    Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-beta1/Smad signaling.
    Eur J Pharmacol. 2021;900:174013.
    PubMed     Abstract available
    
    
    May 2021
46. BUNBUPHA S, Prasarttong P, Poasakate A, Maneesai P, et al
    Imperatorin alleviates metabolic and vascular alterations in high-fat/high-fructose diet-fed rats by modulating adiponectin receptor 1, eNOS, and p47(phox) expression.
    Eur J Pharmacol. 2021;899:174010.
    PubMed     Abstract available
    
    
    
47. DOGHRI Y, Dubreil L, Lalanne V, Helissen O, et al
    Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome.
    Eur J Pharmacol. 2021;899:173978.
    PubMed     Abstract available
    
    
    April 2021
48. SILVA EAP, Carvalho JS, Dos Santos DM, Oliveira AMS, et al
    Cardiovascular effects of farnesol and its beta-cyclodextrin complex in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Apr 2:174060. doi: 10.1016/j.ejphar.2021.174060.
    PubMed     Abstract available
    
    
    March 2021
49. POORGOLIZADEH E, Homayouni Moghadam F, Dormiani K, Rezaei N, et al
    Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!
    Eur J Pharmacol. 2021;894:173851.
    PubMed     Abstract available
    
    
    February 2021
50. ZHANG Y, Luo W, Li H, Yu G, et al
    Larger endothelium-dependent contractions in iliac arteries of adult SHRs are attributed to differential downregulation of TP and EP3 receptors in the vessels of WKYs and SHRs during the transition from adolescence to adulthood.
    Eur J Pharmacol. 2021;893:173828.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: